BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22611701)

  • 1. [The use of different forms of naltrexone in the treatment of opioid dependence].
    Krupitskiĭ EM; Zvartau EE; Blokhina EA; Woody G
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(11 Pt 2):66-72. PubMed ID: 22611701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable extended-release naltrexone for opioid dependence.
    Woody GE; Metzger DS
    Lancet; 2011 Aug; 378(9792):664-5; author reply 666. PubMed ID: 21856476
    [No Abstract]   [Full Text] [Related]  

  • 3. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
    Lobmaier PP; Kunøe N; Gossop M; Waal H
    CNS Neurosci Ther; 2011 Dec; 17(6):629-36. PubMed ID: 21554565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
    Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting depot formulations of naltrexone for heroin dependence: a review.
    Krupitsky EM; Blokhina EA
    Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.
    Krupitsky E; Zvartau E; Woody G
    Curr Psychiatry Rep; 2010 Oct; 12(5):448-53. PubMed ID: 20640538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naltrexone: Not Just for Opioids Anymore.
    Sudakin D
    J Med Toxicol; 2016 Mar; 12(1):71-5. PubMed ID: 26546222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.
    Waal H; Frogopsahl G; Olsen L; Christophersen AS; Mørland J
    Eur Addict Res; 2006; 12(3):138-44. PubMed ID: 16778434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy].
    Krupitsky EM; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):49-56. PubMed ID: 25591636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in naltrexone implants and depot injections for opiate abuse: the new kid on the block is approaching adulthood.
    Brewer C; Streel E
    Adicciones; 2010; 22(4):285-91. PubMed ID: 21152846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence.
    Xuyi W; Juelu W; Xiaojun X; Haiyan L; Zheyuan L; Zhehui G; Guoming D; Gang L; Jin L; Wei H
    Am J Addict; 2014; 23(2):162-9. PubMed ID: 24107112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy.
    Degenhardt L; Gibson A; Mattick RP; Hall W
    Drug Alcohol Rev; 2008 Jan; 27(1):1-3. PubMed ID: 18034375
    [No Abstract]   [Full Text] [Related]  

  • 15. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.
    Larney S; Gowing L; Mattick RP; Farrell M; Hall W; Degenhardt L
    Drug Alcohol Rev; 2014 Mar; 33(2):115-28. PubMed ID: 24299657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injectable extended-release naltrexone for opioid dependence.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Aug; 378(9792):665; author reply 666. PubMed ID: 21856477
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.
    Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE
    Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial.
    Dakwar E; Kleber HD
    J Subst Abuse Treat; 2015 Jun; 53():60-3. PubMed ID: 25819700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
    Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV
    Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK; Morris N; Arnold-Reed D; Tait RJ
    Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.